" class="no-js "lang="en-US"> Terrence Higgins Trust, - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Terrence Higgins Trust | Pharmtech Focus

Terrence Higgins Trust,

About Terrence Higgins Trust,

Terrence Higgins Trust,

Terrence Higgins Trust is at the forefront of the fight against HIV and improving the nation’s sexual health. Our vision is a world where people with HIV live healthy lives free from prejudice and discrimination, and good sexual health is a right and reality for all. Our mission is to: – End the transmission of HIV in the UK. – Empower and support people living with HIV to lead healthy lives. – Amplify the voices of those affected by HIV across public and political arenas to eradicate stigma and discrimination. – Enable people to enjoy good sexual health.